AI could speed up cancer testing for digestive tumors
NCT ID NCT07274579
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is developing and testing an AI model that automatically interprets CLDN18.2 protein levels in digestive system tumors. Researchers will use thousands of pathology samples from multiple hospitals to see if the AI can read test results as accurately as human experts. The goal is to make CLDN18.2 testing more consistent and efficient, which could help guide personalized treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- deep learning-based automatic interpretation model
- What this could lead to
- If successful, this could provide a reliable, automated way to read CLDN18.2 tests, helping doctors choose targeted treatments for digestive cancers.
- What could go wrong
- This is an early-stage validation study, not a treatment trial. The AI model may not perform well in all real-world settings or on different types of samples.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE ONCOLOGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
-
Qianfoshan Hospital
Jinan, Shandong, 250014, China